Evidence map›Paper›PMID 31143189›Full record

ArticleFrontiers in immunology2019

Myo1f, an Unconventional Long-Tailed Myosin, Is a New Partner for the Adaptor 3BP2 Involved in Mast Cell Migration.

Arnau Navinés-Ferrer, Erola Ainsua-Enrich, Eva Serrano-Candelas, Joan Sayós, Margarita Martin

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. MYO1F regulates antifungal immunity by regulating acetylation of microtubules.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  9. MYO1F Regulates IgE and MRGPRX2-Dependent Mast Cell Exocytosis.Journal of immunology (Baltimore, Md. : 1950) · 2021
    Article
  10. Review
  11. Long-Tailed Unconventional Class I Myosins in Health and Disease.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Arnau Navinés-FerrerBiochemistry Unit, Biomedicine Department, Faculty of Medicine, University of Barcelona, Barcelona, Spain.
Erola Ainsua-EnrichBiochemistry Unit, Biomedicine Department, Faculty of Medicine, University of Barcelona, Barcelona, Spain.
Eva Serrano-CandelasBiochemistry Unit, Biomedicine Department, Faculty of Medicine, University of Barcelona, Barcelona, Spain.
Joan SayósImmune Regulation and Immunotherapy Group, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Autonomous University of Barcelona, Barcelona, Spain.
Margarita MartinBiochemistry Unit, Biomedicine Department, Faculty of Medicine, University of Barcelona, Barcelona, Spain.
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESUniversitat de Barcelona · ESUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mast cell chemotaxis is essential for cell recruitment to target tissues, where these cells play an important role in adaptive and innate immunity. Stem cell factor (SCF) is a major chemoattractant for mast cells. SCF binds to the KIT receptor, thereby triggering tyrosine phosphorylation in the cytoplasmic domain and resulting in docking sites for SH2 domain-containing molecules, such as Lyn and Fyn, and the subsequent activation of the small GTPases Rac that are responsible for cytoskeletal reorganization and mast cell migration. In previous works we have reported the role of 3BP2, an adaptor molecule, in mast cells. 3BP2 silencing reduces FcεRI-dependent degranulation, by targeting Lyn and Syk phosphorylation, as well as SCF-dependent cell survival. This study examines its role in SCF-dependent migration and reveals that 3BP2 silencing in human mast cell line (LAD2) impairs cell migration due to SCF and IgE. In that context we found that 3BP2 silencing decreases Rac-2 and Cdc42 GTPase activity. Furthermore, we identified Myo1f, an unconventional type-I myosin, as a new partner for 3BP2. This protein, whose functions have been described as critical for neutrophil migration, remained elusive in mast cells. Myo1f is expressed in mast cells and colocalizes with cortical actin ring. Interestingly, Myo1f-3BP2 interaction is modulated by KIT signaling. Moreover, SCF dependent adhesion and migration through fibronectin is decreased after Myo1f silencing. Furthermore, Myo1f silencing leads to downregulation of β1 and β7 integrins on the mast cell membrane. Overall, Myo1f is a new 3BP2 ligand that connects the adaptor to actin cytoskeleton and both molecules are involved in SCF dependent mast cell migration.

Indexed as

Actin CytoskeletonAdaptor Proteins, Signal Transducingcdc42 GTP-Binding ProteinCell LineCell MovementChemotaxisHumansImmunoglobulin EMast CellsMyosin Type IProto-Oncogene Proteins c-kitRAC2 GTP-Binding Proteinrac GTP-Binding ProteinsRNA, Small InterferingSignal TransductionStem Cell FactorAdaptor Proteins, Signal Transducingcdc42 GTP-Binding ProteinImmunoglobulin EMYO1F protein, humanMyosin Type IProto-Oncogene Proteins c-kitRAC2 GTP-Binding Proteinrac GTP-Binding ProteinsRNA, Small InterferingSH3BP2 protein, humanStem Cell Factoradaptor moleculescell migration and adhesioncytoske letonKIT signalingmast cellsunconventional myosins

Identifiers

PMID31143189
PMCPMC6521229
OpenAlexW2944277268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.